Last reviewed: June 5, 2026
Last updated: June 5, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide and other GLP-1 receptor agonists have transformed weight management for millions, with clinical trials showing 15–22% body weight reduction in one year. However, if you're planning pregnancy, understanding how these medications interact with fertility and fetal development is essential. This guide addresses the science behind GLP-1 use and pregnancy planning.
Does Semaglutide Affect Fertility and Pregnancy Planning?
Semaglutide itself has not been shown to directly impair egg or sperm quality in humans. Animal reproduction studies conducted during drug development did not reveal safety signals at therapeutic doses. However, the medication is not studied as safe during pregnancy, and manufacturers recommend discontinuation before conception.
Rapid weight loss in the months before pregnancy may temporarily affect menstrual regularity and ovulation in some individuals, particularly those with significant obesity-related metabolic changes. This effect is typically reversible; once weight stabilizes, hormonal balance often returns within 2–3 months. Conversely, excess body weight itself can reduce fertility in both sexes, making pre-conception weight loss potentially beneficial when timed correctly.
The key consideration is timing: stopping semaglutide 2–3 months before attempting conception allows the medication to clear your system and metabolic function to stabilize. This window often permits continued weight-loss benefits while establishing baseline fertility parameters.
What Does Clinical Evidence Say About GLP-1 Use in Early Pregnancy?
No large-scale human trials have evaluated semaglutide safety during pregnancy. The FDA classifies it as Pregnancy Category C, meaning animal studies do not demonstrate fetal harm but human data is lacking. Accidental exposure during early pregnancy has been reported in clinical practice, but systematic safety data remain limited.
Gestational diabetes risk is lower in individuals who achieve healthy pre-conception weight, making weight loss before pregnancy a genuine health advantage. However, once pregnancy is confirmed, GLP-1 therapy is discontinued to prioritize fetal development. Some obstetricians recommend waiting until after breastfeeding ends before restarting, though individual medical circumstances vary widely.
Discussing your specific reproductive timeline with your primary care provider or reproductive endocrinologist is essential. They can assess your individual risk factors, metabolic history, and fertility status to create a personalized plan that aligns with both weight management and family planning goals.
Timing Semaglutide Therapy Around Conception
A practical approach involves three phases: pre-conception weight loss, active conception attempts, and post-pregnancy considerations. During the pre-conception phase (3–12 months before attempting pregnancy), semaglutide can support steady weight loss while you establish regular menstrual cycles and metabolic stability. PlexusDx Semaglutide Injection, starting at $149 per month, offers a cost-effective way to reach a healthier baseline weight.
Once you begin active conception attempts, most fertility specialists recommend discontinuing semaglutide to eliminate any theoretical risk and to allow hunger and appetite regulation to normalize. This shift also supports adequate caloric intake if pregnancy occurs. After delivery, your healthcare provider can determine whether to resume GLP-1 therapy based on postpartum recovery, breastfeeding status, and metabolic goals.
Genetic factors influence how your body responds to weight-loss medications and metabolism overall. PlexusDx Precision Peptide Genetic Test identifies your unique GLP-1 receptor sensitivity and appetite-regulation pathways, helping optimize your pre-conception weight-loss strategy with medications and doses tailored to your biology.
Managing Weight Without GLP-1 During Pregnancy and Breastfeeding
During pregnancy, weight gain is expected and necessary for fetal development and milk supply. The focus shifts from weight loss to metabolic health: balanced nutrition, regular movement appropriate for pregnancy, and blood-sugar management to reduce gestational diabetes risk. Many gains from pre-conception weight loss persist despite pregnancy-related weight gain.
Breastfeeding itself burns 300–500 calories daily, supporting postpartum weight loss naturally in many individuals. Adequate protein intake, whole grains, and hydration support milk production while preventing rapid muscle loss. Once breastfeeding ends or your provider clears you for medication restart, resuming semaglutide can accelerate weight-loss goals—without disrupting the metabolic gains you achieved before conception.
PlexusDx supports both planning and execution: begin with Semaglutide Injection during pre-conception (starting at $149/mo), pause during pregnancy and breastfeeding, and restart when clinically appropriate. No membership fees or insurance required means uninterrupted access whenever you and your healthcare provider agree the timing is right.
Common Concerns: Safety, Medications, and Medical Oversight
Many individuals worry about 'wasting' weight loss achieved with semaglutide if they pause therapy during conception. Research shows that weight regain is gradual and often partial, especially if lifestyle habits established during treatment (better food choices, portion awareness, movement) continue. This residual benefit minimizes the pressure to rush back into medication immediately after weaning.
Some patients ask whether compounded semaglutide differs from brand-name Ozempic in pregnancy considerations. PlexusDx semaglutide comes from licensed 503A compounding pharmacies meeting FDA standards for sterility and potency. The active compound is identical; pregnancy safety guidelines apply equally across all semaglutide sources. Always verify your provider's guidance on your specific formulation.
Comprehensive medical oversight is non-negotiable. Your OB/GYN, reproductive endocrinologist, or primary care physician should know you are considering or using GLP-1 therapy so they can monitor metabolic markers, hormone levels, and any treatment adjustments. PlexusDx operates nationwide without insurance requirements, but coordination with your personal medical team remains essential for safe, integrated care.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I get pregnant while taking semaglutide?
Semaglutide does not prevent pregnancy. However, it is not studied as safe during pregnancy, so manufacturers and most clinicians recommend stopping the medication when conception is confirmed or actively being attempted.
How long should I stop semaglutide before trying to get pregnant?
Most fertility and obstetric specialists recommend discontinuing semaglutide 2–3 months before attempting conception. This timeline allows the medication to fully clear your system, your appetite regulation to normalize, and baseline menstrual cycles to re-establish—all factors that support successful conception and early pregnancy health.
Does weight loss from semaglutide improve fertility?
Yes, weight loss itself often improves fertility outcomes, especially in individuals with obesity-related hormonal imbalances. However, very rapid weight loss can temporarily disrupt ovulation.
What is the cost of PlexusDx semaglutide for pre-conception weight loss?
PlexusDx Semaglutide Injection starts at $149 per month across all commitment tiers—your dose may increase, but your price will not. No insurance or membership is required, and the medication is HSA/FSA eligible, making it affordable for long-term pre-conception planning.
Can the Precision Peptide Genetic Test help with pre-conception weight loss?
Yes. PlexusDx Precision Peptide Genetic Test identifies your unique appetite-regulation and metabolic pathways by analyzing key variants like GLP1R rs6923761 and MC4R rs17782313.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can a Healthy Person Take Ozempic for Weight Loss?
NAD+ Semaglutide Side Effects — What You Need to Know